The stock of Fortress Biotech Inc (FBIO) has gone down by -6.83% for the week, with a 15.76% rise in the past month and a -1.55% drop in the past quarter. The volatility ratio for the week is 8.36%, and the volatility levels for the past 30 days are 7.91% for FBIO. The simple moving average for the last 20 days is 0.96% for FBIO stock, with a simple moving average of 2.88% for the last 200 days.
Is It Worth Investing in Fortress Biotech Inc (NASDAQ: FBIO) Right Now?
The 36-month beta value for FBIO is also noteworthy at 1.68. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for FBIO is 21.93M, and at present, short sellers hold a 12.84% of that float. The average trading volume of FBIO on December 13, 2024 was 711.89K shares.
FBIO) stock’s latest price update
Fortress Biotech Inc (NASDAQ: FBIO)’s stock price has decreased by -4.02 compared to its previous closing price of 1.99. However, the company has seen a -6.83% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-14 that Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2024. Lindsay A.
Analysts’ Opinion of FBIO
Many brokerage firms have already submitted their reports for FBIO stocks, with ROTH MKM repeating the rating for FBIO by listing it as a “Buy.” The predicted price for FBIO in the upcoming period, according to ROTH MKM is $10 based on the research report published on March 15, 2024 of the current year 2024.
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see FBIO reach a price target of $6. The rating they have provided for FBIO stocks is “Buy” according to the report published on August 04th, 2022.
The Benchmark Company gave a rating of “Buy” to FBIO, setting the target price at $9 in the report published on October 02nd of the previous year.
FBIO Trading at 5.81% from the 50-Day Moving Average
After a stumble in the market that brought FBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.88% of loss for the given period.
Volatility was left at 7.91%, however, over the last 30 days, the volatility rate increased by 8.36%, as shares surge +22.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.25% upper at present.
During the last 5 trading sessions, FBIO fell by -6.34%, which changed the moving average for the period of 200-days by -7.69% in comparison to the 20-day moving average, which settled at $1.8923. In addition, Fortress Biotech Inc saw -36.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FBIO starting from ROSENWALD LINDSAY A MD, who purchase 763,359 shares at the price of $1.84 back on Sep 23 ’24. After this action, ROSENWALD LINDSAY A MD now owns 3,657,264 shares of Fortress Biotech Inc, valued at $1,404,581 using the latest closing price.
ROSENWALD LINDSAY A MD, the President, CEO & Chairman of Fortress Biotech Inc, purchase 5,000 shares at $7.48 during a trade that took place back on Jul 11 ’24, which means that ROSENWALD LINDSAY A MD is holding 127,500 shares at $37,418 based on the most recent closing price.
Stock Fundamentals for FBIO
Current profitability levels for the company are sitting at:
- -1.7 for the present operating margin
- 0.6 for the gross margin
The net margin for Fortress Biotech Inc stands at -0.81. The total capital return value is set at -1.87. Equity return is now at value -256.45, with -34.95 for asset returns.
Based on Fortress Biotech Inc (FBIO), the company’s capital structure generated 0.72 points at debt to capital in total, while cash flow to debt ratio is standing at -1.9. The debt to equity ratio resting at 2.54. The interest coverage ratio of the stock is -8.52.
Currently, EBITDA for the company is -133.64 million with net debt to EBITDA at -0.12. When we switch over and look at the enterprise to sales, we see a ratio of 1.05. The receivables turnover for the company is 5.86for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.23.
Conclusion
In summary, Fortress Biotech Inc (FBIO) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
